Showing papers by "Noemi Reguart published in 2014"
TL;DR: This review aims to summarize the main mechanisms of AR to EGFR TKI and some clinical strategies that can be used in the daily clinical practice to overcome this resistance and try to prolong the outcomes in this subgroup of patients.
122 citations
TL;DR: The maximum tolerated dose of vorinostat plus erlotinib was used as recommended dose for the phase II (RDP2) to assess the efficacy of the combination, and the combination has no meaningful activity in EGFR-mutated NSCLC patients after TKI progression.
81 citations
TL;DR: Improved understanding of mechanisms underlying resistance to EGFR TKIs emphasises the importance of a genotype-guided approach to therapy and the need to target innovative therapeutic approaches and improve the efficacy of anticancer regimes in NSCLC.
77 citations
TL;DR: Investigating two ALK IHC antibodies and an automated ALK FISH scanning system in a series of non-small cell lung cancer tumor samples found the specificity of these ultrasensitive IHC assays may obviate the need for FISH confirmation in positive IHC cases.
Abstract: Background
Based on the excellent results of the clinical trials with ALK-inhibitors, the importance of accurately identifying ALK positive lung cancer has never been greater. However, there are increasing number of recent publications addressing discordances between FISH and IHC. The controversy is further fuelled by the different regulatory approvals. This situation prompted us to investigate two ALK IHC antibodies (using a novel ultrasensitive detection-amplification kit) and an automated ALK FISH scanning system (FDA-cleared) in a series of non-small cell lung cancer tumor samples.
Methods
Forty-seven ALK FISH-positive and 56 ALK FISH-negative NSCLC samples were studied. All specimens were screened for ALK expression by two IHC antibodies (clone 5A4 from Novocastra and clone D5F3 from Ventana) and for ALK rearrangement by FISH (Vysis ALK FISH break-apart kit), which was automatically captured and scored by using Bioview's automated scanning system.
Results
All positive cases with the IHC antibodies were FISH-positive. There was only one IHC-negative case with both antibodies which showed a FISH-positive result. The overall sensitivity and specificity of the IHC in comparison with FISH were 98% and 100%, respectively.
Conclusions
The specificity of these ultrasensitive IHC assays may obviate the need for FISH confirmation in positive IHC cases. However, the likelihood of false negative IHC results strengthens the case for FISH testing, at least in some situations.
65 citations
TL;DR: In this paper, the authors reviewed several trials evaluating the efficacy of denosumab in comparison with zoledronic acid in patients with solid osteotropic tumors in the setting of skeleton-invading cancers.
Abstract: Introduction: The skeleton is generally the primary, and sometimes the only, site of metastasis in patients with advanced solid tumors. Bone metastases are the most frequent cause of cancer-related pain and the origin of severe morbidity in patients. Among the treatment options available for the prevention of skeletal-related events (SREs) associated with bone metastasis, zoledronic acid, an antiresorptive treatment from the group of bisphosphonates, is currently the standard of care in this setting. Areas covered: Zoledronic acid, together with denosumab (a monoclonal antibody against the receptor activator of nuclear factor kappa B ligand), is the most frequent approach for the prevention of cancer-related events in skeleton. This paper reviews several trials evaluating the efficacy of denosumab in comparison with zoledronic acid in patients with solid osteotropic tumors. In this setting of skeleton-invading cancers, denosumab was demonstrated to be superior to zoledronic acid in preventing or delaying ...
24 citations
TL;DR: The clinical evidence of first line treatment strategy with EGFR TKI is summarized, the potential options in the sequence of treatment in EGFR-mutant patients are discussed, and combined strategies such as intercalated or concurrent EG FR TKI plus chemotherapy are discussed.
23 citations
TL;DR: Although assessable in cytological samples, biopsies are preferred when available for ALK evaluation by FISH, and the ALK translocation prevalence and the associated clinico-pathological features in Spanish NSCLC patients are similar to those previously reported.
19 citations
TL;DR: Olaparib, a PARP-inhibitor, can reduce BRCA1 expression and could improve PFS in this subset of patients when added to an EGFR TKI, and a phase IB study confirmed activity and tolerance of olaparIB plus gefitinib in the absence of pharmacokinetic interactions.
Abstract: TPS8127 Background: EGFR tyrosine kinase inhibitors (TKIs) are considered the treatment of choice for p with advanced NSCLC harboring EGFR mutations, with higher response rate (RR) and longer progr...
5 citations
TL;DR: This randomized phase II/III trial was designed to assess the clinical activity of MK-3475 monotherapy compared with standard docetaxel in patients with advanced NSCLC whose disease has progressed after platinum-containing therapy.
Abstract: TPS8124 Background: Docetaxel is a standard second line treatment for patients with advanced non-small cell lung cancer (NSCLC). It yields a low response rate (~10.5%), limited 1-year survival rate...
5 citations